• PDF
    lock
    Disease education / Fact Sheet
    Spinal Muscular Atrophy (SMA) Factsheet

    Novartis and AveXis combine, aiming to transform the care of SMA, the #1 genetic cause of infant mortality.

  • PDF
    lock
    Corporate Responsibility / Fact Sheet
    Strengthening our Global Health & Corporate Responsibility function

    The factsheet “Strengthening our Global Health & Corporate Responsibility function” provides an overview of our Global Health & Corporate Responsibility governance, structure, strategic priorities and commitments.

  • PDF
    lock
    Corporate Responsibility / Fact Sheet
    Building trust with society: our priorities

    The fact sheet “Building trust with society: our priorities” provides key highlights around 4 areas: pricing and access to medicines; global health challenges; ethical standards; and corporate responsibility.

  • PDF
    lock
    Novartis Social Business / Report
    Novartis Access one-year report

    The Novartis Access one-year report describes first results, early learnings and challenges from our first twelve months on the ground. It also includes external perspectives and country updates, showcasing the progress we have made as we roll out the program.

  • PDF
    lock
    Novartis Access / Report
    Novartis Access two-year report

    Since 2015, Novartis Access has worked to deliver treatments for chronic diseases in lower-income countries. Read our two-year report for an in-depth look at results, learnings and challenges on the ground so far. It includes external perspectives and country updates, showcasing the progress we have made as we roll out the program.

  • PDF
    lock
    Corporate Responsibility / Report
    Corporate Responsibility Report 2017

    As a leading healthcare company, we have a responsibility to help people get access to the treatments they need, no matter where they live. Our CR Performance Report gives you all the facts on the progress we are making. It is issued at the same time as our Annual Report to provide readers with a more integrated view of Novartis.

  • PDF
    lock
    Novartis Social Business / Report
    Healthy Family 10-year report

    10 years ago we launched the Healthy Family program, Novartis first social business model, to improve health via education, affordable products and health services. This report provides information on how the program has evolved since then. It includes external perspectives and country updates, showcasing the learnings and progress we have made over the years.

  • PDF
    lock
    Publications / Report
    Novartis Annual Report 2017

    The Annual Report provides an overview of our strategy and reviews the performance of Novartis in 2017.

  • PDF
    lock
    Publications / Report
    Novartis Annual Report 2018

    Our Annual Report 2018 provides a comprehensive overview of Novartis, including our corporate governance, compensation practices, and operating and financial results.

  • PDF
    lock
    Corporate Responsibility / Report
    Malaria Futures for Africa

    MalaFA (Malaria Futures for Africa) is an opinion research study commissioned by Novartis to capture the views of African malaria experts in 15 sub-Saharan African countries – from government, the research community and NGOs – on progress and remaining challenges toward the 2030 global malaria goals. Study co-chairs are Dr Richard Kamwi, Ambassador, Elimination 8 (E8), and Professor Bob Snow, of the KEMRI-Wellcome Trust programme, Kenya and University of Oxford, United Kingdom.

  • PDF
    lock
    Publications / Report
    Novartis in Society Report

    Transparent reporting has been a central part of our CR commitment for many years, and we continue to make progress in this area. Our Novartis in Society Report (formerly the Corporate Responsibility Report) is issued at the same time as our Annual Report to provide readers with a more integrated view of Novartis.

  • PDF
    lock
    Publications / Report
    Novartis in Society US Report 2018

    Our stakeholders have important questions about our business practices in the United States, including our approach to price adjustments, patient assistance, investment in research and development, and marketing. The Novartis in Society US report aims to help answer those questions.